13 Nov 2022

Uttarakhand: Important Decision Regarding Ban On Medicines Of Baba Ramdev's Divya Pharmacy, This Order Issued

Dehradun: An order asking Yoga Guru Baba Ramdev's Divya Pharmacy to stop the manufacture of five medicines for diabetes, blood pressure, goitre, glaucoma and high cholesterol has been withdrawn by the Uttarakhand Ayurveda and Unani Licensing Authority.

Rectifying the earlier order, the authority on Saturday issued a fresh one permitting the firm to continue the production of these medicines.
The drug controller of the state health authority GCN Jangpangi said there was an error in the previous order dated November 9.
Acharya Balkrishna expressed his gratitude to state govt: Ramdev's close aide Acharya Balkrishna expressed his gratitude to the state government for rectifying the error.
In its earlier order, the Authority had asked Divya Pharmacy to stop the production of five of its products -- Bpgrit, Madhugrit, Thyrogrit, Lipidom tablets and Eyegrit Gold tablets -- which were being promoted as medicines for blood pressure, diabetes, goitre, glaucoma and high cholesterol.
The previous order said the company could resume production of these products only after the authority approved their revised formulation sheets.

Divya Pharmacy strongly objected to the government's order: But the order issued by the Ayurveda department created a stir. As soon as the order of Ayurveda Department was issued, Divya Pharmacy strongly objected to the government's order and the company came to the rescue, justifying its medicines. In a statement issued by Divya Pharmacy, it was said that this order has been made under a conspiracy to defame the indigenous pharmaceutical company.

Complaint was lodged by a Kerala doctor: The action was taken after a complaint was filed by a doctor from Kerala, K V Babu, in which he had accused Divya Pharmacy of violating the Drugs and Magic Remedies (objectionable advertisement) Act and Drugs and Cosmetic Act.
Babu had lodged his complaint against the firm with the Authority in July and followed it up with another via email on October 11.

No comments:

Post a Comment